TCGA-BH-A0H7-01A-13R-A056-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 23
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- CHOLESTEROL_HOMEOSTASIS+0.380
- ESTROGEN_RESPONSE_EARLY+0.380
- PROTEIN_SECRETION+0.370
- APICAL_JUNCTION+0.330
- ESTROGEN_RESPONSE_LATE+0.320
- HEDGEHOG_SIGNALING+0.320
- APICAL_SURFACE+0.310
- GLYCOLYSIS+0.300
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.300
- ALLOGRAFT_REJECTION-0.290
- TNFA_SIGNALING_VIA_NFKB-0.280
- G2M_CHECKPOINT-0.220
- MITOTIC_SPINDLE-0.180
- INFLAMMATORY_RESPONSE-0.160
- E2F_TARGETS-0.130
- MYC_TARGETS_V2-0.090
- INTERFERON_GAMMA_RESPONSE-0.080
- MYC_TARGETS_V1-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A1-A0SJ-01A-11R-A084-07 | — | B | 0.724 |
| 2 | 20060030.TNBC | — | F | 0.715 |
| 3 | TCGA-A2-A0CS-01A-11R-A115-07 | — | C | 0.705 |
| 4 | MBCProject_1151_T1_RNA | — | B | 0.701 |
| 5 | TCGA-CR-5247-01A-01R-2016-07 | — | — | 0.698 |
| 6 | MNG484 | — | — | 0.697 |
| 7 | 4df6c488-ef2f-4019-a1b0-3a3624039be8 | — | — | 0.697 |
| 8 | TCGA-AN-A03X-01A-21R-A00Z-07 | — | A | 0.695 |
| 9 | c119f5ef.864c.434b.b515.57c27c7ae949 | — | cohortA1 | 0.682 |
| 10 | TCGA-CV-7183-01A-11R-2016-07 | — | — | 0.681 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.380 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.310 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |